Onconic Therapeutics Income Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	46,651	14,838	21,056	95	60
Revenue Growth (YoY)	529.90%	-29.53%	22064.25%	58.33%	-
Cost of Revenue	12.05	3.78	2.37	14,933	8,402
Gross Profit	46,639	14,835	21,054	-14,838	-8,342
Selling, General & Admin	25,057	8,087	2,463	-	-
Research & Development	8,603	10,929	15,761	-	-
Amortization of Goodwill & Intangibles	1.18	1.18	1.18	-	-
Other Operating Expenses	118.91	164.15	138.3	-	-
Operating Expenses	34,265	19,632	18,823	-	-
Operating Income	12,374	-4,798	2,231	-14,838	-8,342
Interest Expense	-14.05	-664.16	-1,776	-1,078	-6,831
Interest & Investment Income	1,275	942.63	863.01	1,431	18.85
Currency Exchange Gain (Loss)	865.26	2,020	-79.65	-	-
Other Non Operating Income (Expenses)	-0.05	-7,442	-576.09	52.86	5.74
EBT Excluding Unusual Items	14,500	-9,942	662.51	-14,432	-15,149
Gain (Loss) on Sale of Assets	-	-	-0.7	-	-
Pretax Income	14,501	-9,942	661.81	-14,432	-15,149
Income Tax Expense	-2,253	-1,849	-1,021	-	-
Net Income	16,754	-8,093	1,682	-14,432	-15,149
Net Income to Common	16,754	-8,093	1,682	-14,432	-15,149
Shares Outstanding (Basic)	-	33	2	23	23
Shares Outstanding (Diluted)	-	33	2	23	23
Shares Change (YoY)	-	1314.60%	-90.00%	0.94%	-
EPS (Basic)	-	-247.45	727.75	-624.23	-661.40
EPS (Diluted)	-	-247.45	727.75	-624.23	-661.40
Free Cash Flow	7,082	-7,982	2,983	-17,536	-8,861
Free Cash Flow Per Share	-	-244.07	1290.10	-758.49	-386.90
Gross Margin	99.97%	99.98%	99.99%	-	-
Operating Margin	26.52%	-32.33%	10.60%	-15618.48%	-13903.24%
Profit Margin	35.91%	-54.54%	7.99%	-15191.48%	-25247.72%
Free Cash Flow Margin	15.18%	-53.79%	14.16%	-18458.96%	-14769.11%
EBITDA	12,931	-4,345	2,691	-14,770	-8,292
EBITDA Margin	27.72%	-29.28%	12.78%	-	-
D&A For EBITDA	556.58	452.67	460.13	67.43	49.65
EBIT	12,374	-4,798	2,231	-14,838	-8,342
EBIT Margin	26.52%	-32.33%	10.60%	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.